Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
Sorbonne Université · Assistance Publique – Hôpitaux de Paris · +7 more institutions
Abstract
Pharmacogenetic determinants of the response of patients to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug. The effect of these determinants on clinical outcomes after an acute myocardial infarction is unknown.
We consecutively enrolled 2208 patients presenting with an acute myocardial infarction in a nationwide French registry and receiving clopidogrel therapy. We then assessed the relation of allelic variants of genes modulating clopidogrel absorption (ABCB1), metabolic activation (CYP3A5 and CYP2C19), and biologic activity (P2RY12 and ITGB3) to the risk of death from any cause, nonfatal stroke, or myocardial infarction during 1 year of follow-up.
Citation impact
- FWCI
- 130.15
- Percentile
- 100%
- References
- 38
Authors
10- TSTabassome SimonCorresponding
Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Hôpital Bichat-Claude-Bernard
- CVCéline Verstuyft
Université Paris-Sud, Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard
- MMMurielle Mary‐Krause
Inserm, Hôpital Bichat-Claude-Bernard
- LQLina Quteineh
Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard
- ÉDÉlodie Drouet
Assistance Publique – Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard
Topics & keywords
- Medicine
- Clopidogrel
- Internal medicine
- Hazard ratio
- Myocardial infarction
- Percutaneous coronary intervention
- CYP2C19
- Stroke (engine)
- Good health and well-being